Ivan Kairatov is a distinguished biopharma expert with a deep background in research and development, specifically focusing on the evolution of oncological therapies and high-tech drug delivery systems. He has spent years analyzing how technological shifts in molecular engineering redefine patient outcomes, particularly in the competitive landscape of lung and breast cancer. Today, he joins us to discuss the recent clinical milestones achieved by Merck and Kelun-Biotech, exploring how their collaborative efforts in antibody-drug conjugates are poised to disrupt traditional chemotherapy standards.
How do antibody-drug conjugates like sac-TMT fundamentally change the delivery of toxic payloads compared to traditional treatments?
The shift from traditional chemotherapy to antibody-drug conjugates, or ADCs, is like moving from a broad-spectrum blast to a precision-guided strike. In the past, patients had to endure a blast of chemotherapy that killed diseased and healthy cells alike, often leading to debilitating side effects that limited the dosage we could safely administer. With a drug like sac-TMT, we are seeing a more targeted approach where the toxic payload is delivered directly to the tumor cells, sparing the surrounding healthy tissue from unnecessary damage. This precision is why Merck views sac-TMT as a cornerstone of its future portfolio, as it allows for a much more potent hit against the cancer while keeping the body’s overall system from being thrown off kilter. By refining the delivery mechanism, we are finally moving past the therapeutic bottlenecks that have historically stalled progress in difficult-to-treat populations.
What is the significance of the recent Phase 3 study results involving sac-TMT and its performance against standard chemotherapy?
The data coming out of the recent Phase 3 study in China represents a groundbreaking proof-of-concept for the industry. Specifically, the trial showed that sac-TMT helped patients with non-squamous non-small cell lung cancer stave off disease progression significantly better than the standard chemotherapy regimen. Even though the detailed figures remain under wraps for now, the independent monitoring board confirmed a statistically significant and clinically meaningful improvement in progression-free survival. This is particularly vital because the trial focused on patients whose tumor cells lack the PD-L1 protein, a group that has long been a therapeutic bottleneck for oncologists. Seeing a positive trend in overall survival in this “negative” population suggests that we are on the verge of a new front-line treatment standard that could eventually replace traditional chemo.
How does Merck’s investment strategy, including its $1 billion commitment to ADC technology, reflect the broader shifts in the pharmaceutical industry?
Merck is betting big on the idea that ADCs will define the next decade of cancer care, as evidenced by their willingness to strike deals potentially worth billions of dollars with partners like Kelun-Biotech. Their $1 billion investment in Seagen and the subsequent exploration of the ADC class show a clear desire to replicate the massive commercial success seen by competitors in the breast cancer space. Currently, Merck has 17 Phase 3 studies underway to test sac-TMT across a wide range of indications, from gastrointestinal and genitourinary systems to gynecological cancers. This level of aggressive expansion demonstrates that they don’t just see this as a niche product, but as a universal platform that can be adapted for multiple tumor types. By diversifying their trials into lung and endometrial cancers, they are building a robust clinical momentum that is hard for any other player to ignore.
Could you explain why the PD-L1 protein level is such a critical factor in determining the success of these new combination therapies?
The PD-L1 protein essentially acts as a gatekeeper for the immune system, helping it focus on killing diseased cells rather than healthy ones. When a patient is PD-L1 negative, it creates a massive challenge because traditional immunotherapies like Keytruda often struggle to find their target, leaving these patients with very few options outside of harsh chemotherapy. Sac-TMT is the first antibody-drug conjugate to succeed in a Phase 3 study for this specific “negative” population when combined with immunotherapy. This success proves that even when the immune system’s natural targeting is off kilter, the ADC can provide the necessary bridge to deliver the treatment effectively. It opens the door for thousands of patients who previously hit a therapeutic wall, offering them a more refined and effective way to fight metastatic disease.
What is your forecast for the role of antibody-drug conjugates in front-line cancer treatment over the next five years?
I expect that ADCs will transition from being a secondary option to becoming the absolute cornerstone of front-line treatment for both lung and breast cancers. We are already seeing sac-TMT win approvals in China for four different indications, and as Merck’s 17 global Phase 3 trials begin to mature, the pressure to move away from systemic chemotherapy will become undeniable. The clinical momentum we are witnessing suggests that the “targeted payload” model will soon be the standard of care, significantly improving progression-free survival rates across the board. In five years, the conversation will likely shift from whether we should use ADCs to how we can combine them with other biologics to eliminate the need for traditional chemotherapy entirely. This will result in a more humane and effective treatment landscape where the focus is entirely on the molecular signature of the tumor.
